Our family office has invested in a company that has created a unique and highly innovative patented technology based on biologically active materials manufactured from allogenic human blood plasma. These Plasma-based Bioactive Materials (PBMs) contain highly concentrated natural regenerative factors that promote healing and reduce infections in multiple clinical settings. As a result, they help lower healthcare costs.

The company has patented a process which fine-tunes the release of active biologics on a staged basis (days/weeks/months) when the body needs them most to accelerate healing. The company has successfully developed multiple forms, such as pastes, putties, scaffolds, plugs and screws, using pooled plasma from healthy donors with its proprietary cross-linking process. The first product, Bone Healing Accelerant, has been designed to treat severe bone fractures, through accelerated bone healing of the fracture and surrounding soft tissues while reducing complications, infections and duration of care. Early clinical evidence suggests that the company’s initial product is efficacious, safe, consistent and affordable.

Our family office has been the lead investor in this company since 2011 and have participated in every round (Series A & B) as well as leading this Convertible Note which is intended to get the company to an IPO in early 2020. The company anticipates IND approval for its Phase III trial in August 2019 after which it will use the proceeds of the IPO to fund the Phase III trials (US and EU). The price and terms of this deal are highly attractive, and this company is poised to disrupt large addressable markets with its technology. Most of the management team has come out of Johnson & Johnson and the technology came out of Carnegie Mellon University.

There is approximately $2.0M available of this $7.5M convertible round which will close before the end of this year. Please contact us to receive information about this opportunity.